-DOCSTART- -X- O
Vaccination -X- _ O
is -X- _ O
the -X- _ O
process -X- _ O
of -X- _ O
administering -X- _ O
immunogenic -X- _ O
formulations -X- _ O
in -X- _ O
order -X- _ O
to -X- _ O
induce -X- _ O
or -X- _ O
harness -X- _ O
antigen -X- _ O
( -X- _ O
Ag -X- _ O
) -X- _ O
-specific -X- _ O
antibody -X- _ O
and -X- _ O
T -X- _ O
cell -X- _ O
responses -X- _ O
in -X- _ O
order -X- _ O
to -X- _ O
protect -X- _ O
against -X- _ O
infections. -X- _ O
Important -X- _ O
successes -X- _ O
have -X- _ O
been -X- _ O
obtained -X- _ O
in -X- _ O
protecting -X- _ O
individuals -X- _ O
against -X- _ O
many -X- _ O
deleterious -X- _ O
pathological -X- _ O
situations -X- _ O
after -X- _ O
parenteral -X- _ O
vaccination. -X- _ O
However -X- _ O
, -X- _ O
one -X- _ O
of -X- _ O
the -X- _ O
major -X- _ O
limitations -X- _ O
of -X- _ O
the -X- _ O
current -X- _ O
vaccination -X- _ O
strategies -X- _ O
is -X- _ O
the -X- _ O
administration -X- _ B-Intervention
route -X- _ I-Intervention
that -X- _ O
may -X- _ O
not -X- _ O
be -X- _ O
optimal -X- _ O
for -X- _ O
the -X- _ O
induction -X- _ O
of -X- _ O
immunity -X- _ O
at -X- _ O
the -X- _ O
site -X- _ O
of -X- _ O
pathogen -X- _ O
entry -X- _ O
, -X- _ O
i.e. -X- _ O
, -X- _ O
mucosal -X- _ O
surfaces. -X- _ O
It -X- _ O
is -X- _ O
now -X- _ O
well -X- _ O
documented -X- _ O
that -X- _ O
immune -X- _ O
responses -X- _ O
along -X- _ O
the -X- _ O
genital -X- _ O
, -X- _ O
respiratory -X- _ O
, -X- _ O
or -X- _ O
gastrointestinal -X- _ O
tracts -X- _ O
have -X- _ O
to -X- _ O
be -X- _ O
elicited -X- _ O
locally -X- _ O
to -X- _ O
ensure -X- _ O
efficient -X- _ O
trafficking -X- _ O
of -X- _ O
effector -X- _ O
and -X- _ O
memory -X- _ O
B -X- _ O
and -X- _ O
T -X- _ O
cells -X- _ O
to -X- _ O
mucosal -X- _ O
tissues. -X- _ O
Moreover -X- _ O
, -X- _ O
needle-free -X- _ O
mucosal -X- _ B-Outcome
delivery -X- _ I-Outcome
of -X- _ I-Outcome
vaccines -X- _ I-Outcome
is -X- _ I-Outcome
advantageous -X- _ I-Outcome
in -X- _ I-Outcome
terms -X- _ I-Outcome
of -X- _ I-Outcome
safety -X- _ I-Outcome
, -X- _ I-Outcome
compliance -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
ease -X- _ I-Outcome
of -X- _ I-Outcome
administration. -X- _ I-Outcome
However -X- _ O
, -X- _ O
the -X- _ B-Outcome
quest -X- _ I-Outcome
for -X- _ I-Outcome
mucosal -X- _ I-Outcome
vaccines -X- _ I-Outcome
is -X- _ I-Outcome
challenging -X- _ I-Outcome
due -X- _ I-Outcome
to -X- _ I-Outcome
( -X- _ I-Outcome
1 -X- _ I-Outcome
) -X- _ I-Outcome
the -X- _ I-Outcome
fact -X- _ I-Outcome
that -X- _ I-Outcome
Ag -X- _ I-Outcome
sampling -X- _ I-Outcome
has -X- _ I-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
performed -X- _ I-Outcome
across -X- _ I-Outcome
the -X- _ I-Outcome
epithelium -X- _ I-Outcome
through -X- _ I-Outcome
a -X- _ I-Outcome
relatively -X- _ I-Outcome
limited -X- _ I-Outcome
number -X- _ I-Outcome
of -X- _ I-Outcome
portals -X- _ I-Outcome
of -X- _ I-Outcome
entry -X- _ I-Outcome
; -X- _ I-Outcome
( -X- _ I-Outcome
2 -X- _ I-Outcome
) -X- _ I-Outcome
the -X- _ I-Outcome
deleterious -X- _ I-Outcome
acidic -X- _ I-Outcome
and -X- _ I-Outcome
proteolytic -X- _ I-Outcome
environment -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
mucosae -X- _ I-Outcome
that -X- _ I-Outcome
affect -X- _ I-Outcome
the -X- _ I-Outcome
stability -X- _ I-Outcome
, -X- _ I-Outcome
integrity -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
retention -X- _ I-Outcome
time -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
applied -X- _ I-Outcome
Ags -X- _ I-Outcome
; -X- _ I-Outcome
and -X- _ I-Outcome
( -X- _ I-Outcome
3 -X- _ I-Outcome
) -X- _ I-Outcome
the -X- _ I-Outcome
tolerogenic -X- _ I-Outcome
environment -X- _ I-Outcome
of -X- _ I-Outcome
mucosae -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
requires -X- _ I-Outcome
the -X- _ I-Outcome
addition -X- _ I-Outcome
of -X- _ I-Outcome
adjuvants -X- _ I-Outcome
to -X- _ I-Outcome
elicit -X- _ I-Outcome
efficient -X- _ I-Outcome
effector -X- _ I-Outcome
immune -X- _ I-Outcome
responses. -X- _ I-Outcome
Until -X- _ O
now -X- _ O
, -X- _ O
only -X- _ O
few -X- _ O
mucosally -X- _ O
applicable -X- _ O
vaccine -X- _ O
formulations -X- _ O
have -X- _ O
been -X- _ O
developed -X- _ O
and -X- _ O
successfully -X- _ O
tested. -X- _ O
In -X- _ O
animal -X- _ O
models -X- _ O
and -X- _ O
clinical -X- _ O
trials -X- _ O
, -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
lipidic -X- _ O
structures -X- _ O
such -X- _ O
as -X- _ O
liposomes -X- _ O
, -X- _ O
virosomes -X- _ O
, -X- _ O
immune -X- _ O
stimulating -X- _ O
complexes -X- _ O
, -X- _ O
gas-filled -X- _ O
microbubbles -X- _ O
and -X- _ O
emulsions -X- _ O
has -X- _ O
proven -X- _ O
efficient -X- _ O
for -X- _ O
the -X- _ O
mucosal -X- _ O
delivery -X- _ O
of -X- _ O
associated -X- _ O
Ags -X- _ O
and -X- _ O
the -X- _ O
induction -X- _ O
of -X- _ O
local -X- _ O
and -X- _ O
systemic -X- _ O
immune -X- _ O
reponses. -X- _ O
Such -X- _ O
particles -X- _ O
are -X- _ O
suitable -X- _ O
for -X- _ O
mucosal -X- _ O
delivery -X- _ O
because -X- _ O
they -X- _ O
protect -X- _ O
the -X- _ O
associated -X- _ O
payload -X- _ O
from -X- _ O
degradation -X- _ O
and -X- _ O
deliver -X- _ O
concentrated -X- _ O
amounts -X- _ O
of -X- _ O
Ags -X- _ O
via -X- _ O
specialized -X- _ O
sampling -X- _ O
cells -X- _ O
( -X- _ O
microfold -X- _ O
cells -X- _ O
) -X- _ O
within -X- _ O
the -X- _ O
mucosal -X- _ O
epithelium -X- _ O
to -X- _ O
underlying -X- _ O
antigen-presenting -X- _ O
cells. -X- _ O
The -X- _ O
review -X- _ O
aims -X- _ O
at -X- _ O
summarizing -X- _ O
recent -X- _ O
development -X- _ O
in -X- _ O
the -X- _ O
field -X- _ O
of -X- _ O
mucosal -X- _ B-Patient
vaccination -X- _ I-Patient
using -X- _ O
lipid-based -X- _ O
particles. -X- _ O
The -X- _ O
modularity -X- _ O
ensured -X- _ O
by -X- _ O
tailoring -X- _ O
the -X- _ O
lipidic -X- _ O
design -X- _ O
and -X- _ O
content -X- _ O
of -X- _ O
particles -X- _ O
, -X- _ O
and -X- _ O
their -X- _ O
known -X- _ O
safety -X- _ O
as -X- _ O
already -X- _ O
established -X- _ O
in -X- _ O
humans -X- _ O
, -X- _ O
make -X- _ O
the -X- _ O
continuing -X- _ O
appraisal -X- _ O
of -X- _ O
these -X- _ O
vaccine -X- _ O
candidates -X- _ O
a -X- _ O
promising -X- _ O
development -X- _ O
in -X- _ O
the -X- _ O
field -X- _ O
of -X- _ O
targeted -X- _ O
mucosal -X- _ B-Patient
vaccination -X- _ I-Patient
. -X- _ O

